Form 4: Benitec Biopharma Grants Executive Director Stock Options

Benitec Biopharma has granted its Executive Director, Megan Boston, 720,000 stock options that will vest quarterly starting March 31, 2025.

Summary

• Benitec Biopharma Inc. has granted 720,000 stock options to its Executive Director, Megan Boston.
• The options have an exercise price of $12.18.
• The options will vest in 16 substantially equal quarterly installments.
• The vesting period will commence on March 31, 2025.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of executive compensation, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.

Positives

• The granting of stock options can serve as an incentive for the Executive Director to perform well.
• The vesting schedule aligns the Executive Director's interests with the long-term performance of the company.

Risks

• The value of the stock options is dependent on the future performance of Benitec Biopharma's stock price.
• If the stock price does not increase above the exercise price, the options may not be valuable to the Executive Director.

Future Outlook

The stock options will vest over a four-year period, incentivizing long-term performance.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech industry, similar to companies like Alnylam Pharmaceuticals and CRISPR Therapeutics.
• The vesting schedule of 16 quarterly installments is a typical approach to ensure long-term commitment from executives, comparable to vesting schedules seen in other biotech firms.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the Executive Director to improve company performance.
• The Executive Director is directly impacted by the vesting schedule and the potential value of the options.

Key Dates

Keywords

stock options, executive compensation, vesting, Benitec Biopharma, Megan Boston